Metrics to compare | AIDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAIDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −1.1x | −0.3x | |
PEG Ratio | 0.37 | −0.05 | 0.00 | |
Price/Book | 3.0x | 1.7x | 2.6x | |
Price / LTM Sales | 2.4x | 0.9x | 3.0x | |
Upside (Analyst Target) | - | 75.1% | 58.6% | |
Fair Value Upside | Unlock | 21.9% | 8.4% | Unlock |
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.